Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Current Assets for 16 consecutive years, with $917.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets changed N/A to $917.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $917.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $917.0 million for FY2025, N/A changed from the prior year.
  • Current Assets for Q4 2025 was $917.0 million at Cytokinetics, down from $977.3 million in the prior quarter.
  • The five-year high for Current Assets was $1.1 billion in Q2 2024, with the low at $364.2 million in Q2 2021.
  • Average Current Assets over 5 years is $718.5 million, with a median of $638.7 million recorded in 2024.
  • The sharpest move saw Current Assets skyrocketed 91.7% in 2021, then tumbled 36.51% in 2023.
  • Over 5 years, Current Assets stood at $535.7 million in 2021, then skyrocketed by 48.45% to $795.2 million in 2022, then dropped by 21.02% to $628.1 million in 2023, then soared by 62.18% to $1.0 billion in 2024, then decreased by 9.98% to $917.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $917.0 million, $977.3 million, and $886.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.